Join
Live feed
·
PRReleasevia Quantisnow
Amarin Corporation plc logo

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

ByQuantisnow·Wall Street's wire, on your screen.
AMRN· Amarin Corporation plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AMRN (Amarin Corporation plc) and more on Quantisnow.